Updated:
SCIENS GROUP RISK SERVICES LIMITED
Sciens Group pairs life-science direct investments with structured credit from Waterloo, UK — a managed-risk hybrid rare among European multi-family...
SCIENS GROUP RISK SERVICES LIMITED
Founded in 1996 by Marc J. Brenner and David J. Sarner, Sciens Group Risk Services Limited began as a London-focused private-client advisory before expanding into direct principal investments. The firm's core identity rests on blending traditional family-office wealth preservation with life-science and fintech direct investment, a niche uncommon among European multi-family offices of its size. Sciens Group emphasizes managed-risk frameworks applied to illiquid positions, a posture shaped by its founders' backgrounds in private banking and structured finance. Sciens Group deploys capital across three principal asset classes: life-science direct equity, fintech venture, and private credit. Within life sciences, the firm targets clinical-stage biopharma and medical-device companies with regulatory catalysts in Europe and Israel. Fintech exposure has historically focused on payment infrastructure and regtech platforms. The private-credit book consists of structured loans to growth-stage companies in the same sectors, often alongside equity warrants. Known historical portfolio exposures include positions in Israeli medical-device ventures and UK-based fintech platforms (per public record). The geographic footprint spans the United Kingdom, Continental Europe, and Israel. The firm operates from Waterloo, United Kingdom and has historically maintained a compact team, with headcount estimates in the range of 10 to 20 professionals (Altss estimate). In May 2024, Sciens Group confirmed the continuation of its managed-risk overlay mandate across all direct investments, reinforcing the structured-finance discipline that differentiates its deployment approach from pure equity-focused family offices. Sciens Group's structural differentiator is its explicit mandate to run a managed-risk framework across both liquid and illiquid exposures, a posture more common in insurance-linked asset managers than in multi-family offices. The firm structures its direct investments with downside-protection covenants and synthetic risk-transfer mechanisms where available, creating a convexity-driven return profile that aims to outperform traditional buy-and-hold family-office portfolios in down markets.
General information
Firm type
Multi Family Office
Year founded
1996
AUM
$50M - $150M (Altss estimate)
Location
Region
Europe
Country
United Kingdom
City
Waterloo
Corporate office
Waterloo, United Kingdom
Principals
Marc J. Brenner
CEO
David J. Sarner
Chairman
Sector focus
Frequently asked questions
Who runs investment decisions at Sciens Group?
Marc J. Brenner, CEO and co-founder, leads investment decisions alongside Chairman David J. Sarner. Both have private-banking backgrounds and shape the firm's risk-managed deployment approach across life sciences, fintech, and private credit. Decisions are made by a concentrated investment committee rather than a large analyst team, consistent with the firm's boutique structure.
How does Sciens Group source its direct-investment deal flow?
Sciens Group sources through a combination of founder networks in European private banking, life-science research institution relationships in the UK and Israel, and fintech accelerator pipelines. The firm's compact size and London adjacency give it access to mid-market opportunities that larger institutional managers typically bypass. Co-investment relationships with European family offices also generate shared deal flow.
Does Sciens Group participate in fund commitments or only direct deals?
Sciens Group primarily executes direct investments and structured credit transactions. The firm does not publicly market itself as a fund-of-funds investor and has not disclosed significant third-party fund commitments. Its private-credit book operates with a direct-origination model, structuring bespoke loans to growth-stage companies rather than buying into pooled credit vehicles.
What is Sciens Group's managed-risk overlay and how does it work?
The managed-risk overlay is a structured-finance discipline applied to the firm's illiquid direct investments. The firm uses downside-protection covenants, synthetic hedges, and structured payout profiles to reduce permanent capital loss risk. This approach reflects the founders' banking backgrounds and distinguishes Sciens Group from multi-family offices that take plain-vanilla equity positions.
Which sectors does Sciens Group explicitly avoid?
Sciens Group does not publicly invest in commodity extraction, heavy industrials, or speculative cryptocurrency ventures. The firm's mandate stays within regulated life-science, fintech infrastructure, and structured credit. Consumer-facing technology and traditional real estate have not been disclosed as active allocations, keeping the portfolio concentrated in sectors where the principals have direct underwriting expertise.
How is Sciens Group related to other Sciens-named entities?
Sciens Group Risk Services Limited is the UK-incorporated operating entity. The Sciens brand also extends to affiliated entities in the life-science and managed-account space, though the exact corporate relationships are not fully public. The Waterloo-based entity houses the multi-family office and risk-managed direct-investment functions, separate from any US-incorporated Sciens vehicles.
What is Sciens Group's known posture on co-investments alongside external GPs?
Sciens Group co-invests alongside European family offices and niche life-science specialists. The firm has not disclosed a formal co-investment club but participates in syndicated deals where the structured-credit overlay can be applied to negotiated terms. External GP relationships tend to be bilateral rather than through a public co-investment program.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: